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Triple negative or basal-like breast cancer (TNBC) is characterised by aggressive progression, lack 
of standard therapies and poorer overall survival rates for patients. The bad prognosis, high rate of 
relapse and resistance against anticancer drugs have been associated with a highly abnormal loss 
of redox control in TNBC cells. Here, we developed docetaxel (DTX)-loaded micellar-like 
nanoparticles (MLNPs), designed to address the aberrant TNBC biology through the placement of 
redox responsive cross-links designed into a terpolymer. The MLNPs were derived from 
poly(ethyleneglycol)-b-poly(lactide)-co-poly(N3--ε-caprolactone) with a disulfide linker 
pendant from the caprolactone regions in order to cross-link adjacent chains. The terpolymer 
contained both polylactide and polycaprolactone to provide a balance of accessibility to reductive 
agents necessary to ensure stability in transit, but rapid micellar breakdown and concomitant drug 
release, when in breast cancer cells with increased levels of reducing agents. The empty micellar-
like nanoparticles did not show any cytotoxicity in vitro in 2D monolayers of MDA-MB-231 
(triple-negative breast cancer), MCF7 (breast cancer) and MCF10A (normal breast epithelial cell 
line), whereas DTX-loaded reducible crosslinked MLNPs exhibited higher cytotoxicity against 
TNBC and breast cancer cells which present high intracellular levels of glutathione. Crosslinked 
and non-crosslinked MLNPs showed high and concentration-dependent cellular uptake in 
monolayers and tumour spheroids, including when assessed in co-cultures of TNBC cells and 
cancer-associated fibroblasts. DTX loaded crosslinked MLNPs showed the highest efficacy 
against 3D spheroids of TNBC, in addition the MLNPs also induced higher levels of apoptosis, as 
assessed by annexin V/PI assays and increased caspase 3/7 activity in MDA-MB-231 cells in 
comparison to cells treated with DTX-loaded un-crosslinked MLNP (used as a control) and free 
DTX. Taken together these data demonstrate that the terpolymer micellar-like nanoparticles with 
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reducible crosslinks have high efficacy in both 2D and 3D in vitro cancer models by targeting the 
aberrant biology, i.e. loss of redox control of this type of tumour, thus may be promising and 
effective carrier systems for future clinical applications in TNBC. 
INTRODUCTION  
Triple negative breast cancer (TNBC) is a subtype of breast cancer which lacks the expression 
of estrogen (ER) and progesterone receptors (PR) and also the overexpression of human epidermal 
growth factor receptor 2 (HER 2), according to the established immunohistochemical profile. It is 
considered one of the most aggressive types of breast cancer [1-3].   
Compared to other types of breast cancer, TNBC patients tend to have a poor prognosis, high 
recurrence, frequent early visceral metastasis and elevated risk of death [4]. In part, this is due to 
the difficulty in eradicating TNBC tumours after pre-operative chemotherapy [5]. Unfortunately, 
patients diagnosed with TNBC cannot take advantage of targeted treatments available for other 
breast cancer treatments such as hormonal therapy and anti-HER2 agents due to the lack of ER, 
PR and HE2 receptors [6]. Since there are no standard treatments for TNBC, patients are usually 
treated with a combination of surgery, radiation and conventional chemotherapy including taxanes 
and anthracyclines. However, these drugs are associated with various side effects including acute 
and long-term toxicity, which could contribute to the low overall survival of TNBC patients.[7] 
Hence, there is an urgent need to develop more targeted treatments for this aggressive type of 
breast cancer [8]. 
Due to its aggressiveness and lack of established biomarkers and molecular targets, efforts have 
been made to elucidate the driving mechanism and also to establish distinct markers that guide in 
understanding the features of TNBC. Recently, it has been demonstrated that the glutathione 
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biosynthesis pathway plays a role in the development of TNBC and it is associated with the 
prevention of cell death and also with poorer patient outcomes. Moreover, one of the causes of 
high relapse in TNBC patients is the existence and survival of cancer stem cells that are 
characterised by increased amounts of intracellular glutathione (GSH) levels [9-11]. Thus, it might 
be possible to exploit the specific and unusual biological features of triple negative breast cancer 
in order to provide targeted treatments for this highly aggressive subtype of breast cancer [12].   
Targeted nanoparticles have the possibility to overcome problems related to chemotherapy by 
protecting administered drugs from early degradation, reducing toxicity and other side effects, 
improving intracellular penetration and by providing the drugs with longer circulation half-lives 
[13, 14]. Further advances for TNBC treatment include the use of stimuli-responsive materials, 
which can be designed to recognise a particular microenvironment and respond to it by means of 
a disease-specific local stimulus [15-17].  
Many drug delivery systems have been designed to exploit the different concentrations of 
glutathione (GSH) in the intracellular and extracellular compartments, and in the tumour 
microenvironment [18]. In addition to the well-known role of GSH as a cellular antioxidant, in the 
preservation of redox homeostasis, and in the immune response of cells, it is also established that 
high levels of GSH can also confer resistance to cancer cells against certain chemotherapeutic 
drugs, contributing to the growth and maintenance of tumours. This has been especially observed 
in breast, bone marrow, colon, larynx and lung cancers [19-22]. As mentioned above, GSH has 
been reported as an important therapeutic target in TNBC, thus exploiting the enhanced GSH levels 
by using redox-responsive nanocarriers to release drugs that are not themselves redox-active, is an 
appealing route to site-specific TNBC therapies.  
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These types of materials can be designed by using disulfide bonds that will be cleaved by GSH 
when the particle enters cancer cells, followed by the release of the drug at a high local 
concentration for maximum efficacy [23-25]. However, the placement of the disulfide bonds is 
critical to the function of the nanocarrier, as GSH is a hydrophilic molecule which must be able to 
access the disulfide linkages in order to affect local drug release. In addition, extracellular reducing 
species can be present which may act on exposed nanocarrier disulfide linkages to cause non-site-
specific drug release, thus there is a trade-off between accessibility and reactivity of disulfide 
components which must be addressed in any bio-reductively activated drug delivery system [26]. 
In the present study, we prepared candidate drug-delivery materials of micellar-like nanoparticles 
(MLNPs) from terpolymers of poly(ethyleneglycol)-poly(lactide)-co-poly(azido)caprolactone 
(PEG-b-PLA-co-(N3-PCL)). We also prepared a related terpolymer, but with the poly(lactide) 
units replaced with unfunctionalised polycaprolactone (PEG-b-PCL-co-(N3-PCL)). These polymer 
nanoparticles were subsequently cross-linked by reaction of the azides pendant from the 
caprolactone units with disulfide-containing bis(alkynes). The chemistries were designed to 
generate materials with the same reducibly-cleavable functionality, but in one case ‘diluted’ with 
polylactide functionality and in the second case with more caprolactone units, with which we 
aimed to probe the question of disulfide accessibility without ‘over-exposure’ and the effects of 
glutathione in breast cancer cells. The interiors of the MLNPs thus varied by having less 
hydrophobic PLA-co-N3-PCL units compared to the PCL-co-N3-PCL components but both had 
the same outer sterically-stabilising PEG shell [27-29]. In this way, we aimed to evaluate access 
of GSH into the disulfide-rich regions, ensuring that micelle opening and drug release could only 
take place once the polymers were installed in regions of abnormally high GSH content, as in 
TNBC cells (Figure 1). The crosslinking of micellar-based nanomedicines has been successfully 
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used for addressing the stability issues of this type of delivery system which directly affects their 
in vivo efficacy [30]. Indeed there have been many reducibly-activated crosslinked systems and 
GSH-responsive approaches which have been designed to increase the in vivo efficacy of polymer-
mediated drug delivery to tumours [30-32]. In addition, there have been examples of polymer 
micelles with cores cross-linked via non-cleavable carbon-carbon bond formation, epoxy-amine 
chemistries, active ester-nucleophile combinations and amide-bond forming reactions to enhance 
the overall stability of the delivery system in transit in vivo. In other cases, reversible cross-links 
have been formed via polymer carboxylate and platinum complexes,[33] and drug release 
enhanced by rapidly hydrolysable linkers,[34] thus there are multiple routes by which micellar 
drug delivery systems can be optimised for a particular therapeutic application.[35] However, 
many of these systems require complex and laborious organic and/or polymer chemistry methods 
that can complicate their possible clinical translation. Here we aimed to combine easily accessible 
copolymer chemistries with the azide-alkyne 1,3-dipolar cycloaddition reaction (click chemistry) 
in order to obtain cross-linked MLNPs in high-yields, with simple reaction conditions, easy 
purification and less cytotoxic by-products [36, 37]. Therefore, the first target diblock terpolymer 
was synthesised by ring-opening polymerization of α-chloro-ε-caprolactone and lactide using PEG 
(polyethylene glycol) as a macroinitiator. The chloro groups of the polymer were then replaced by 
azide groups to obtain mPEG-b-poly(D,L-lactide-co-α-N3-ε-caprolactone). The second diblock 
terpolymer of mPEG-b-poly(caprolactone)-co-α-N3-ε-caprolactone) was prepared by a similar 
method [38]. Crosslinked MLNPs were subsequently prepared through the use of a bis-alkyne 
crosslinker, which was attached to the polymer by standard azide-alkyne coupling, leading to self-
assembly of the polymer chains into stabilised micellar-like nanoparticles. The resultant materials 
were characterised by dynamic light scattering (DLS), zeta potential measurements and 
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transmission electron microscopy (TEM). High pressure liquid chromatography (HPLC) was used 
for evaluating drug-loading capacities and in vitro drug release.  
We compared the effectiveness and cytotoxicity of the DTX-loaded crosslinked and un-
crosslinked MLNPs and free DTX against triple negative breast cancer cells (MDA-MB-231). The 
un-crosslinked formulation was used as a control for the experiments. Cytotoxicity of the empty 
MLNPs was also evaluated by MTS assays in MDA-MB-231, MCF7 (breast cancer cells), and in 
MCF10A cells, which are from a non-cancerous human breast epithelial cell line. The 
internalisation of Cy5-labelled MLNPs in monolayers and tumour spheroids of MDA-MB-231 and 
co-culture with cancer-associate fibroblasts was evaluated using flow cytometry and confocal 
microscopy, and the capability of the DTX-loaded crosslinked, un-crosslinked MLNPs and free 
DTX to induce apoptosis in MDA-MB-231 cells was studied by using the annexin-V/PI assay. 
The activation of caspase-3/7 was also assessed in the same TNBC cell line after treatment with 
DTX-loaded MLNPs and free drug. DTX-loaded crosslinked MLNPs also had a superior 
effectiveness against 3D spheroids of TNBC in comparison to the other un-crosslinked formulation 
and free drug which was assessed by calcein-AM and ethidium homodimer double staining for 
distinguishing in between live and dead cells. Overall, these in vitro experiments in 2D and 3D 
indicated that crosslinked reductive MLNPs had an increased uptake and selective enhanced 
efficacy on breast cancer cells presenting higher intracellular levels of GSH, including TNBC cells. 
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Figure 1 Outline illustration of DTX-loaded redox-responsive crosslinked micellar-like nanoparticles 
inducing apoptosis in the triple negative breast cancer cell. 
 
EXPERIMENTAL SECTION 
Materials and Methods 
Docetaxel (European Pharmacopoeia standard), 2-chlorocyclohexanone (98%), 3-
chloroperoxybenzoic acid (mCPBA, 70%), monomethoxy poly(ethylene glycol) (mPEG, Mn-
5000 g/mol), tin(II) 2-ethylhexanoate (Sn(Oct)2), (92.5-100%) sodium azide (≥99.5%), 
propargylamine (98%), copper (II) sulfate (99.9%), ascorbic acid sodium salt (≥98%), 2-
hydroxyethyl disulfide (90%), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDAC, 99%), 4-pentynoic acid (95%), ethylenediaminetetraacetic acid (EDTA, 99.4-100%) and 
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deuterated chloroform (CDCl3) were all purchased from Sigma-Aldrich. Cyanine5 (Cy5) alkyne 
fluorescent dye was purchased from Lumiprobe. All solvents were purchased from Fisher 
Scientific. Propidium iodide (PI), Hoechst 33342, CellMaskTM Green plasma membrane stain, 
Dead cell apoptosis kit Annexin-V/PI, CellEventTM Caspase-3/7 Green and LIVE/DEAD® 
Viability/Cytotoxicity Assay Kit were purchased from Thermo Fisher Scientific. CellTiter 96® 
Aqueous One solution of MTS was purchase from Promega. Ultra-low attachment 96-well round 
bottom (black and clear) plates were purchased from Corning Incorporated Life Sciences, USA. 
All chemicals were used as received unless otherwise stated. 
 
Monomer and polymer syntheses 
Synthesis of α-chloro-ε-caprolactone monomer  
The monomer α-chloro-ε-caprolactone was synthesised using a method previously described 
[39]. Briefly, at room temperature, 10 g (40.5 mmol) of mCPBA (70%) was transferred to a flask 
containing a solution of 2-chlorocyclohexanone (5 g, 37.5 mmol) in 50 mL of dichloromethane. 
The reaction was left to run for 96 h and afterwards, the obtained product was cooled to -20oC to 
crystallize the unreacted m-chlorobenzoic acid. The compound was filtered and washed three times 
with saturated solutions of Na2S2O3/ NaCl and NaHCO3. Finally, the organic layer was washed 
with water and dried over MgSO4. Subsequently, the organic phase was filtered and then 
concentrated using a rotary evaporator to obtain a yellow viscous liquid which was purified by 
silica gel flash column chromatography (hexane: ethyl acetate 9:2, Rf 0.36). The yield of the α-
chloro-ε-caprolactone obtained was 3.50 g (70%). 1H NMR (400 MHz, CDCl3, δ in ppm): 4.85-
4.81 (s, 1H), 4.69-4.63 (m, 1H), 4.29-4.23 (m, 1H), 2.23-1.77 (m, 6H). All the characterisation 
data were in accord with prior literature reports for this compound [39]. 
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Synthesis of mPEG-b-poly(D,L-lactide-co-α-Cl-ε-caprolactone) 
The copolymer was synthesised by ROP (ring-opening polymerisation) of α-chloro-ε-
caprolactone and D,L-lactide using mPEG5000 as a macroinitiator and Sn(Oct)2 (tin-II 
ethylexanoate) as a catalyst. D,L-lactide (1.00 g) and chloro-ε-caprolactone (1.03 g) were 
transferred into a flask containing mPEG5000 (5.00 g) which was previously dried by azeotropic 
distillation with anhydrous toluene. The contents were heated at 90oC and solubilized with 10 mL 
of anhydrous toluene added into the sealed flask under nitrogen atmosphere. At this moment, 
Sn(Oct)2 (0.002 g) was added and the reaction was left to proceed at 90
oC for 24 h under stirring. 
Afterwards, the reaction was cooled to room temperature.  The product was dissolved in 
dichloromethane and precipitated in diethyl ether. It was then filtered and dried under reduced 
pressure until constant weight was achieved. A white powder was obtained in a 75% yield. 1H 
NMR (400 MHz, CDCl3, δ in ppm): δ 5.20 (d, J = 6.0 Hz, 5H), 4.28 (dd, J = 37.1, 17.4 Hz, 10H), 
3.67 (s, 320H), 3.41 (s, 2), 2.07 (d, J = 40.1 Hz, 7H), 1.67 – 1.41 (m, 35H). 
Synthesis of mPEG-b-poly(D,L-lactide-co-α-N3-ε-caprolactone) 
The azide-functionalised copolymer was obtained through a substitution reaction between chloro 
and azide groups. Typically, mPEG-b-poly(D,L-lactide-co-α-Cl-ε-caprolactone) (1.00 g) was 
transferred into a flask and dissolved in 3 mL of DMSO (dimethyl sulfoxide). Subsequently, 
sodium azide (0.088 g) was carefully added and the reaction was allowed to proceed for 24 h at 
room temperature. The product was dissolved in a small amount of dichloromethane and extracted 
with diethyl ether to remove DMSO before filtering. The reaction product was then dissolved in 
toluene and centrifuged in order to remove the insoluble salts followed by the precipitation of the 
polymer in diethyl ether. The obtained functionalised copolymer was filtered and dried under 
reduced pressure until constant weight was achieved. A pale yellow powder was obtained in a 
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yield of 0.80 g, (80%). 1H NMR (400 MHz, CDCl3, δ in ppm): δ 5.37 – 5.08 (m, 2H), 4.45 – 4.08 
(m, 2H), 3.67 (s, 133H), 3.40 (s, 1H), 1.70 (d, J = 31.0 Hz, 11H), 1.67 – 1.40 (m, 10H).  
Synthesis of Cy5-labelled mPEG-b-poly(D,L-lactide-co-α-N3-ε-caprolactone) 
Briefly, 110 mg (0.016 mmol) of the copolymer and 10 mg (0.0179 mmol) of Cy5-alkyne were 
added into a flask and dissolved in 2 mL of DMSO. A 265 µL of an ascorbic acid solution 25 
mg/mL was added and the reaction was purged with nitrogen and left stirring. Afterwards, 520 µL 
of copper (II) sulfate solution (10 mg/mL) was added into the flask and the reaction was allowed 
to stir overnight at room temperature. EDTA was added (19.04 mg, 0.065 mmol / 2 eq vs. Cu) and 
the polymer was purified by dialysis in order to remove any unreacted dye. Subsequently, the 
labelled polymer was frozen and lyophilised. The conjugation efficiency was determined by 
fluorescence spectroscopy. 
Synthesis of bis-alkyne ethyl disulfide crosslinker (disulfanediylbis(ethane-2,1-diyl) bis(pent-
4-ynoate) 
Disulfanediylbis(ethane-2,1-diyl) bis(pent-4-ynoate) was synthesised  by adding 1.31 g (8.49 
mmol) of 2-hydroxyethyl disulfide, 3.90 g (20.34 mmol) of N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDAC), and 4-pentynoic acid (2 g, 20.38 mmol) into a flask 
containing anhydrous dichloromethane at 0oC. Afterwards, 4-(dimethylamino) pyridine (0.25 g, 
2.05 mmol) was dissolved in dichloromethane and then was added under stirring and the mixture 
was left to react for 48 h at room temperature. The purification of the bis-alkyne crosslinker was 
carried out by washing the reaction product with the followed solutions: 1M hydrochloric acid (3 
x 100 mL), 1M sodium hydroxide (3 x 100 mL) and 1M NaCl (200 mL). The mixture was then 
dried over MgSO4 and the solvent was removed under reduced pressure. Finally, the crude product 
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was purified by flash column chromatography (hexane: ethyl acetate 4:3) yielding 0.98 g, (75%). 
1H NMR (400 MHz, CDCl3, δ in ppm): 4.39 (t, 4 H), 2.95 (t, 4H), 2.63 – 2.57 (m, 4H), 2.56 – 2.50 
(m, 4H), 2.01 (t, 2H). The characterisation data were in accord with prior literature reports for this 
compound [40]. 
Preparation of empty and docetaxel or Cy5-labelled un-crosslinked micellar-like 
nanoparticles 
In this work, all the micellar formulations were prepared by a dialysis method, using dimethyl 
sulfoxide as the organic solvent inside the dialysis membrane, and water as the bulk phase. In a 
typical experiment, empty MLNPs were prepared by dissolving 12.5 mg of the mPEG-b-poly(D,L-
lactide-co-α-N3-ε-caprolactone) copolymer in 2 mL of dimethyl sulfoxide. The solution was added 
to 10 mL of ultrapure water, while stirring, using a syringe pump (flow rate: 0.1 mL/min). 
Afterwards, the obtained solution was transferred into a dialysis membrane (cut-off 3500 Da) and 
was left dialysing against water for 24 h. DTX-loaded MLNPs were prepared by using 2 mg of 
DTX and 12.5 mg of the copolymer. The method of preparation was similar as described for empty 
MLNPs. Cy5-labelled un-crosslinked MLNPs were prepared as described above, however the 
particles were prepared by using a 50:50 w/w mixture of Cy5-labelled polymer and unlabelled 
polymer. The obtained micellar suspensions were then filtered through a syringe membrane filter 
before further analysis (0.22 µm) (Millex-LG, Millipore Co., USA). The particle size (z-average 
diameter) and zeta potential of all prepared micelles were measured using NanoZS equipment 
(Malvern, UK) at 25oC. Morphology of MLNPs was analysed by transmission electron microscopy 
using a Tecnai G2 (FEI, Oregon, USA). Images were obtained without staining. 
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Preparation of empty and docetaxel or Cy5-labelled crosslinked micellar-like nanoparticles 
Empty crosslinked MLNPs were prepared by dissolving 12.5 mg of the mPEG-b-poly(D,L-
lactide-co-α-N3-ε-caprolactone) and 4.9 mg (0.01 mmol) of bis-alkyne ethyl disulfide crosslinker 
in 2 mL of dimethyl sulfoxide and the mixture was allowed to stir for 2 hours. Afterwards, the 
solution was added dropwise to 10 mL of ultrapure water using a syringe pump (flow rate: 0.1 
ml/min) and then copper(II) sulfate (0.5 mg, 0.003 mmol) and ascorbic acid sodium salt (0.6 mg, 
0.003 mmol) were added. The reaction was run for 24 h at 36oC. Before dialysing the obtained 
product against water (cut-off 3500 Da), EDTA was added (13.03 mg, 0.044 mmol / 2 eq vs. Cu). 
The preparation method for DTX-loaded MLNPs was similar to the method described above in 
which 2 mg of DTX was used for 12.5 mg of copolymer. Cy5-labelled crosslinked MLNPs were 
prepared as described above, however the particles were prepared by using a 50:50 w/w mixture 
of Cy5-labelled polymer and unlabelled polymer. The methods used to characterise crosslinked 
MLNPs were similar to those described for un-crosslinked MLNPs. In order to assess 
responsiveness to redox environments, empty crosslinked MLNPs were treated with 10 mmolar 
GSH solution in PBS for 4 h and the differences in the morphology and size were observed by 
checking samples by DLS and TEM (Figure 3).  
Drug content and encapsulation efficiency 
The quantification of DTX in the MLNPs was determined using a HPLC-DAD (Shimadzu, 
Prominence, Japan) quantification method. The HPLC system was equipped with a photodiode 
array (PDA) detector and autosampler. LC solution software was used to analyse the 
chromatograms. A Phenomenex Aeris C18 column at room temperature (150 x 4.6 mm, 3.6 µm) 
was used and the mobile phase consisted of water: acetonitrile (60:40) at a flow rate of 0.7 mL/min. 
The method was previously validated for specificity, linearity, accuracy and precision. In short, 1 
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mg of MLNPs were dissolved and sonicated in 5 mL of acetonitrile, after which the solution was 
filtered and transferred to the vial for quantification. The analysis was performed in triplicate. The 
injection volume was 10 µL and DTX was detected at 224 nm. The encapsulation efficiency was 
expressed as the percentage of drug loaded into the MLNPs (Table 1). 
In vitro drug release study 
The release rate of DTX from the crosslinked MLNPs was measured in a reductive (10 mM of 
GSH in PBS) and non-reductive (PBS without GSH) media. The non-reductive media was used as 
a control for the experiment. The DTX released from the un-crosslinked MLNPs was also 
measured in PBS without GSH. In all the three samples prepared, 0.1% of tween 20 (polysorbate 
20) was added to help with the solubilisation of DTX. Briefly, 3 mg of freeze-dried crosslinked 
and un-crosslinked MLNPs were dissolved in 0.8 mL of PBS (0.1% tween 20) and the solution 
was placed in a dialysis device (Slide-A-Lyzer, Thermo Scientific). The DXT-loaded MLNPs were 
left dialysing against 2 mL of the mentioned release media in a shaking water bath at 37oC. 
Aliquots of 200 µL were taken at each time point and the collected samples were replaced with 
the same volume of fresh media to maintain sink conditions. The amount of DTX present in each 
aliquot was analysed by HPLC using the same method and conditions shown in ‘Drug content and 
encapsulation efficiency’. The cumulative release (%) was defined based on the concentration of 
DTX calculated in the samples collected at different time points and considering the initial amount 





Cell lines, culture and development of 3D tumour spheroids model 
Breast cancer MCF7, triple negative breast cancer cell line MDA-MB-231 and the non-
cancerous human mammary epithelial cells MCF10A were acquired from the American Type 
Culture Collection (Manassas, VA). Cancer-associated fibroblasts (CAFs) were obtained as 
previously shown [41]. In brief, samples of fresh surgical materials from tumour resections at 
Nottingham University Hospitals NHS Trust were used after being approved the appropriate 
Research Ethics Committees as shown elsewhere [41]. Samples were then dissected and fixed for 
immunohistochemistry. Afterwards, an amount of minced tumour tissue was disaggregated and 
cultured in DMEM, 10% FBS, 2 mmol/L glucose for the establishment of fibroblasts. The identity 
of CAFs was confirmed by appropriate methods [41]. The cancer cell lines were maintained in 
Dulbecco's modified Eagle's medium (DMEM, Lonza, Inc), supplemented with 10% (v/v) FBS 
and 1% penicillin/ streptomycin and incubated at 37oC in 5% CO2. MCF10A was maintained in 
human mammary epithelial cell growth complete medium which consisted of HuMEC basal serum 
free medium with HuMEC supplemented kit (HuMEC Ready Medium, Gibco).  
TNBC tumour spheroids were obtained using ultra-low attachment (ULA) 96-well round bottom 
plates (Corning, UK). MDA-MB-231 cells were seeded into ULA plates at a density of 4000 per 
well and cells were centrifuged at 300 x g for 3 minutes after seeding to bring the cells closer 
together and aid in the formation of a single spheroid. Spheroids were then cultured for 3 days 
before final analysis or treatment.  
For the 3D co-culture, MDA-MB-231 and GFP-transfected CAFs were seeded in ULA plates at 
a density of 2000:2000 cells per well and the method for obtaining the spheroids was similar to 
the previously described.  
Cell proliferation analysis 
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The cytotoxicity of the empty and DTX-loaded crosslinked and un-crosslinked MLNPs was 
assessed by the MTS 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (CellTiter 96® AQueous One Solution Reagent, Promega) assay. MDA-MB-231, 
MCF7 or MCF10A cells were seeded into a 96 well-plate at a density of 5 x 103 cells per well and 
incubated at 37oC and 5% of CO2 for 24 h. Afterwards, cells were exposed to different 
concentrations of empty MLNPs (100, 250, 500, 750 and 1000 µg/mL) and DTX-loaded MLNPs 
(7-40 µg/mL of DTX) for 24 hours. Controls containing only medium and DMSO were also 
prepared. MLNPs were diluted using complete medium. After the incubation time, 20 µg/mL of 
MTS solution was added in each well and then cells were left incubating for an additional 3 hours. 
Absorbance was measured using a BioTek microplate reader at 490 nm. Experiments were made 
in replicates and repeated in different days and the percentage of metabolic activity (mean %  
SD) was reported compared to the control. For all experiments both technical and biological 
replicates were performed.  
Cell uptake studies 
Cellular uptake in 2D and 3D cell culture  
2D monolayers of TNBC cells assessed by confocal microscopy 
Human triple negative breast cancer monolayers of MDA-MB-231 cells were cultured on micro 
slide 8-well chambers (Ibidi, Germany) at a density of 1 x 104 cells per well for 24 h in DMEM 
complete medium (Lonza, Inc) at 37oC in 5% CO2 for 24 h. Cells were then exposed to Cy5-
labelled crosslinked and un-crosslinked MLNPs at concentrations of 50 µg/mL in the dark for 4 
hours. Following incubation, cells were washed with PBS (phosphate-buffered saline) for three 
times and then fixed with 4% formaldehyde (in PBS) for 10 min and again washed with PBS (3 
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times). Afterwards, cells were exposed to Deep Green plasma membrane staining at the 
concentration of 1 µL/mL (100 µL) for 10 minutes in the dark at 37°C and washed with PBS for 3 
times. Cells were then incubated with Hoechst 33342 dye at concentration of 1 µL/mL (100 µL) 
for 30 minutes in the dark at room temperature and washed again with PBS (three times). Cells 
were imaged with a Zeiss LSM 510 Meta confocal microscope and Zeiss LSM software was used 
for data analyses. 
2D monolayers of TNBC cells assessed by flow cytometry 
MDA-MB-231 cells were cultured on 6-well plates at a density of 7.5 x 104 cells per well for 24 
h in DMEM complete medium (Lonza, Inc) at 37oC in 5% CO2. Cell culture medium was replaced 
with the medium containing Cy5-labelled crosslinked or un-crosslinked MLNPs at concentrations 
of 10, 25, 50, 100 and 150 µg/mL and cells were incubated for 4 h at 37oC in 5% CO2. Medium 
was then removed and cells were washed with PBS 3 times and then detached with 500 µL of 1x 
trypsin/EDTA solution. Cells were centrifuged and resuspended in 500 µL of paraformaldehyde 
solution in PBS (4%) and then analysed by flow cytometry (Beckman Coulter FC 500). Generated 
data were analysed using Kaluza 1.5 software. 
Uptake in 3D tumour spheroids  
Confocal microscopy  
MDA-MB-231 cells were seeded into a ULA 96 well-plate at a density of 4000 per well and the 
spheroids were formed using the same procedure as shown previously.  The spheroids were then 
exposed to 50 µg/mL of Cy5-labelled crosslinked and un-crosslinked MLNPs and they were 
incubated for 5 h at 37°C in 5% CO2. Afterwards, the media was gradually removed and the 
spheroids were carefully washed with PBS 3 times. The spheroids were fixed with 4% 
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formaldehyde (in PBS) for 10 min and again washed with PBS (3 times). The spheroids were then 
stained with Hoechst 33342 dye at concentration of 1 µg/mL (50 µL) for 30 minutes in the dark at 
room temperature and washed again with PBS (three times). Cells were imaged with a Leica TCS 
microscope. Images were processed using LASX software and ImageJ. 
3D co-culture spheroids were obtained by seeding MDA-MB-231 and CAFs in the proportion 
of 2000:2000 cells per well. The spheroids were obtained and treated and prepared for imaging 
using the same procedure previously described. Spheroids were imaged with a Zeiss LSM 880 and 
images were processed using Zen 2 (blue edition).   
Flow Cytometry  
3D spheroids as monoculture (MDA-MB-231 cells) and co-culture (MDA-MB-231 and CAFs) 
were prepared as previously described and treated with 50 µg/mL and 150 µg/mL of Cy5-labelled 
crosslinked and un-crosslinked MLNPs and incubated for 5 h. After the incubation period, the 
spheroids were carefully dissociated using TrypLE™ Express Enzyme (1X). The resultant single 
cell suspensions from nineteen wells per condition/ treatment were pooled together in a 
microcentrifuge tube and cells were centrifuged and washed with PBS 3 times. Samples were 
analysed using a Beckman Coulter FC 500 flow cytometer. Kaluza 1.5 software was used for the 
data analysis.  
Apoptosis assays in 2D monolayers of TNBC 
Annexin-V/ PI  
MDA-MB-231 cells were cultured on 6-well plates at a density of 7.5 x 104 cells per well for 24 
h in DMEM complete medium (Lonza, Inc) at 37oC in 5% CO2. Cell culture medium was replaced 
with the medium containing free DTX, DTX-loaded crosslinked or un-crosslinked MLNPs at the 
concentration of 7 µg/mL (of DTX) or medium in the absence of MLNPs (controls) and cells were 
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incubated for 24 h at 37oC in 5% CO2. After the incubation period, supernatants were collected 
and then adhered cells were detached with 500 µL of 1x trypsin/EDTA solution. Cells were 
centrifuged and washed with PBS. Afterwards, cells were resuspended in 100 µL of 1X annexin-
binding buffer and 2.5 µL annexin-V FITC (Thermo Scientific) and 1 µL of 100 µg/mL PI 
solutions were added. The negative control sample cells were left untreated and unstained, while 
the other two control samples were also left untreated, but the cells were stained with annexin-V 
and PI, respectively. Cells were incubated in the dark for 15 min and then 400 µL of 1X annexin-
binding buffer was added. Samples were immediately analysed using a Beckman Coulter FC 500 
flow cytometer. Kaluza 1.5 software was used for the data analysis as before. 
Detection of caspase-3/7    
As previously described for annexin-V/PI assay, MDA-MB-231 cells were cultured on 6-well 
plates at a density of 7.5 x 104 cells per well for 24 h in DMEM complete medium (Lonza, Inc) at 
37oC in 5% CO2. Cell culture medium was then replaced with the medium containing DTX-loaded 
crosslinked and un-crosslinked MLNPs or free drug at the concentration of 7 µg/mL (of DTX) and 
controls (untreated cells) were also prepared. After the incubation period (24 h at 37oC in 5% CO2), 
supernatants were collected and adhered cells were detached with 500 µL of 1x trypsin/EDTA 
solution for 3 minutes. Cells were washed with PBS, resuspended, and then transferred to the 
FACS tubes. CellEventTM Caspase-3/7 Green Detection reagent at the concentration of 500 µM 
was added to the tubes (1 µL) and cells were incubated for 30 minutes at 37oC protected from 
light. After 25 minutes of incubation, 1 µL SYTOXTM AADvanced red at a concentration of 1 mM 
was added and cells were incubated for a further 5 minutes at 37oC. Samples were then analysed 
without washing or fixing using a Beckman Coulter FC 500 flow cytometer and data were analysed 
using Kaluza 1.5 software. 
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Live/Dead cell staining of TNBC 3D spheroids  
MDA-MB-231 cells were seeded into a ULA 96 well-plate at a density of 4000 per well and the 
spheroids were formed using the same procedure as shown previously. Cell culture medium was 
replaced with the medium containing free DTX, DTX-loaded crosslinked or un-crosslinked 
MLNPs at the concentration of 7 µg/mL (of DTX) or medium in the absence of MLNPs (negative 
control) or 12% of DMSO (positive control) and cells were incubated for 24 h at 37oC in 5% CO2.  
Afterwards, the media was gradually removed and the spheroids were carefully washed with PBS. 
The spheroids were then stained with 2 M of calcein AM and 4 M of EhD-1 solution in PBS 
and incubated for 1 h at room temperature and washed again with PBS (three times).  The spheroids 
were fixed with 4% formaldehyde (in PBS) for 10 min and again washed with PBS (3 times). Cells 
were imaged with a Zeiss 710 confocal microscope. Images were processed using Zeiss Zen 
microscope software. For performing the quantitative live/dead cell assay the experiment were 
performed as shown however, spheroids were disintegrated using TrypLE™ Express Enzyme (1X) 
and cell were analysed using a plate reader.  As before, technical and biological replicates were 
performed. 
Statistical analysis 
Statistical significances were determined using t-test or analysis of variance (one-way and two-
way ANOVA). Values of p < 0.05 were considered statistically significant.   
 
RESULTS AND DISCUSSION 
Synthesis, characterisation and functionalisation of monomer and polymers 
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The α-chloro-ε-caprolactone monomer was synthesised by a Baeyer-Villiger reaction as shown 
in Figure 2A. Oxidation was performed by 3-chloroperoxybenzoic acid (mCPBA) to convert α-
chlorocyclohexanone to α-chloro-ε-caprolactone and ε-chloro-ε-caprolactone in a molar ratio of 
95/5. The crude product was purified by flash column chromatography on silica gel in order to 
obtain the desired monomer, as indicated in the 1H NMR spectrum of the purified product (Figure 
S1). The characterisation data for the obtained compound were in agreement with the reported 
literature data for α-chloro-ε-caprolactone using the same synthetic route [39].  
The novel copolymer mPEG-b-poly(D,L-lactide-co-α-Cl-ε-caprolactone) was synthesised via 
ring-opening polymerization of α-chloro-ε-caprolactone and the D,L-lactide using mPEG5000 as 
macroinitiator and Sn(Oct)2 as a catalyst (Figure 2B). The polymer was characterised by 
1H NMR 
and 13C NMR as shown in Figures S2 and S3. The Mn of the polymer as determined by 
1H NMR 
was 7100 g mol-1, whereas the molar mass obtained from the SEC (size exclusion chromatography) 
(Figure S4) was 11680 g mol-1. Polymer mPEG-b-poly(D,L-lactide-co-α-Cl-ε-caprolactone) 
afforded a narrow molecular weight distribution (1.03) of Mw/Mn at room temperature, according 
to SEC traces of the polymer. Subsequently, the chloro substituents of the mPEG-b-poly(D,L-
lactide-co-α-Cl-ε-caprolactone) polymer were replaced via nucleophilic substitution reactions 
using sodium azide in order to obtain an azide functionalised copolymer (mPEG-b- poly(D,L-
lactide-co-α-N3-ε-caprolactone), as shown in Figure 2C. The reaction was performed in mild 
conditions, e.g. room temperature and using DMSO as the solvent, in order to avoid side reactions 
and formation of by-products. The functionalised polymer was characterised by 1H NMR, 13C 
NMR and Fourier transform infrared spectroscopy (FT-IR) (Figure S5, S6 and S7). As can be 
noticed in Figure S7, the FT-IR spectrum of mPEG-b-poly(D,L-lactide-co-α-N3-ε-caprolactone) 
indicates the characteristic azide peak at ~ 2100 cm-1. The absence of any new carboxylate or OH 
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bands demonstrated that the polymer did not suffer any degradation during the chloro-to-azide 
substitution reaction. Cy5-labelled mPEG-b-poly(D,L-lactide-co-α-N3-ε-caprolactone) polymer 
was obtained through CuAAC (copper catalysed azide- alkyne 1,3-dipolar cycloaddition) reaction 
between the azide groups at the polymer backbone and the alkyne group present in the Cy5-alkyne 
dye (Scheme S1). The conjugation efficiency results determined by fluorescence spectroscopy 
showed that there were 1-1.5 Cy5 units per polymer chain. FT-IR was also used to monitor the 
conjugation of Cy5 to the polymer. As shown in Figure S8 there was a decrease of the azide peak 
of the labelled polymer at ~ 2100 cm-1 after the conjugation reaction in comparison to the non-





Figure 2 (A) Schematic representation of the reaction to obtain α-chloro-ε-caprolactone. (B) Synthesis of 
mPEG-b-poly(D,L-lactide-co-α-Cl-ε-caprolactone) and mPEG-b-poly(D,L-lactide-co-α-N3-ε-
caprolactone). (C)  Self-assembly of un-crosslinked MLNPs. (D) Preparation of redox responsive core 
crosslinked MLNPs by alkyne-azide cycloaddition reaction between mPEG-b-poly(D,L,lactide-co-
α-N3-ε-caprolactone) and crosslinker molecule and dialysis method (E) Self-assembly of 
crosslinked MLNPs by dialysis method. (F) FT-IR of freeze dried MLNPs showing the absence of 
azide peak at about 2100 cm-1 in the crosslinked MLNPs (shown on purple line). (G) Preparation 
of comparator redox responsive core crosslinked MLNPs control through a reaction between 
mPEG-b-poly(ε-caprolactone-co-α-N3-ε-caprolactone) and the responsive crosslinker. The reaction 
and micellization was obtained using the alkyne-azide cycloaddition similarly as shown in Figure 
2D. (H) Preparation of non-responsive core crosslinked MLNPs control using a non-responsive 
linker. The reaction and formulation were prepared as shown in Figure 2D above.   
Preparation and characterisation of crosslinked and un-crosslinked MLNPs 
In this work, a dialysis method was used to prepare both crosslinked and un-crosslinked micellar 
formulations. The un-crosslinked MLNPs were formed from the self-assembly of mPEG-b-
poly(D,L-lactide-co-α-N3-ε-caprolactone) in water, as shown in Figure 2C.  
Crosslinked MLNPs were prepared firstly by the copper catalysed cycloaddition reaction 
between azide groups of the polymer and the alkynes from the synthesised crosslinker, as shown 
in Figure 2D. The bis-alkyne crosslinker was previously synthesised from 2-hydroxyethyl 
disulfide and propargylacetic acid using DMAP and EDC as catalyst and activating agent, 
respectively and was characterised by 1H NMR and 13C NMR (Figure S9 and S10). At the end of 
the micellar core cross-linking reaction, copper sulphate was removed using EDTA to leave self-
assembled nanoparticles crosslinked by 1,2,3-triazole linkages, as shown in Figure 2E.  
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FT-IR was used to monitor the cycloaddition reaction and the formation of core-crosslinked 
MLNPs (Figure 2F) which resulted in the disappearance of the azide band in comparison to the 
un-crosslinked freeze dried MLNPs [42].  
The scheme with the chemical structures used for preparing the mPEG-b-poly(ε-caprolactone-
co-α-N3-ε-caprolactone) crosslinked MLNPs and the non-responsive crosslinked MLNP are 
shown in Figure 2E-H. The characterisation of the polymers and MLNPs and the results before 
and after treatment with GSH are shown in Figure S15-S19 in the supplementary information.  
Characterisation data from the crosslinked and un-crosslinked MLNPs are presented in Figure 3 
and Table 1. The size distributions (hydrodynamic diameter) and zeta potentials were measured 
by light scattering. The morphology of the MLNPs was determined by TEM. The size of the empty 
un-crosslinked MLNPs was 31 nm ± 1, whereas for the crosslinked MLNPs the size was 41 nm ± 
0.5. The larger hydrodynamic diameter of the crosslinked MLNPs was expected, as there were 
likely to be conformational changes regarding the formation of the triazole ring and enhanced 
rigidity in the micellar cores [40].  
MLNPs loaded with DTX were also increased in size, as expected. TEM images presented in 
Figure 3C show that both types of MLNPs presented with spherical morphologies. These data 
suggested that both micellar formulations might be suitable for drug delivery in cancer therapy, as 
it has been reported that nanomedicines in the sub-100 nm range have increased penetration and 
accumulation in tumours [43, 44]. More importantly, it was demonstrated that MLNPs in the 30 – 
50 nm size range showed superior accumulation in tumours, including those of lower 
permeabilities [45]. Thus, the formulations prepared were deemed suitable in terms of size to be 
taken forward for in vitro and in vivo studies.  
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Figure 3 (A) Showing scheme of un-crosslinked MLNPs with free N3 groups, core crosslinked MLNPs 
with redox responsive group and crosslinked MLNPs exposed to GSH 10 mM. (B) Size distribution (DLS) 
of empty crosslinked, un-crosslinked MLNPs and DLS of the redox responsive crosslinked MLNPs after 
the treatment with glutathione (GSH) 10 mM for 3 hours. Size was based on intensity measured by DLS 
(n=3). (C) Morphology of the MLNPs (un-crosslinked, crosslinked and crosslinked after treatment with 
GSH) by transmission electron microscopy. Scale bar 1000 (left), 2000 nm (centre) and 2000 nm (right). 
As shown in Figure 3, redox-responsive crosslinked MLNPs were exposed to 10 mM of GSH for 
3h and the responsiveness of the particles was investigated through the evaluation of the size and 
morphology before and after the treatment. In addition, to corroborate the hypothesis regarding the 
accessibility of the disulfide bond placed in the core of the MLNPs, the same investigation was 
performed for non-responsive crosslinked MLNPs and also, redox-responsive MLNPs obtained 
with the comparison terpolymer mPEG-b-poly(εCL-co-αN3εCL). The characterisation data of the 
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non-responsive linker and terpolymer are shown in SI Figures S17-19. Comparing the copolymers 
designed in this work, mPEG-b-poly(D,L-LA-co-αN3εCL) and mPEG-b-poly(εCL-co-αN3εCL), 
D,L-lactide was substituted by ε-caprolactone with both polymers having a similar molar mass 
(approximately 7 kDa). It is known that PLA is less hydrophobic than PCL, as the latter is a 
semicrystalline polymer, whereas D,L-PLA is an amorphous polymer due to its monomers being 
randomly positioned into the polymer chain [27, 28, 46]. When comparing Figures 4 and S19, 
from the DLS and TEM images it can be noticed that the crosslinked MLNPs prepared using the 
copolymer mPEG-b-poly(D,L-LA-co-αN3εCL) presented increased responsiveness to GSH than 
the MLNPs made from mPEG-b-poly(εCL-co-αN3εCL). Regarding non-responsive crosslinked 
MLNPs, as seen in Figure S19 the particles were not changed in terms of the size or morphology 
after treatment with GSH. In terms of drug release in the presence of GSH, according to the data 
showed, it is expected that the non-responsive crosslinked MLNPs, would not show 
responsiveness to GSH similarly to the un-crosslinked MLNPs, however with better drug retention 
similarly to the crosslinked MLNPs when exposed to PBS only, as shown in Figure 4. 
The results of drug content and encapsulation efficiency are also shown in Table 1, indicating 
that the crosslinked MLNPs exhibited better encapsulation efficiency and higher drug contents 







Table 1 Characterisation data of empty,  Cy5-labelled and DTX-loaded un-crosslinked (un-CC) and redox 
responsive core crosslinked (CC) MLNPs 
Formulation Size (d.nm) ± 
SD 
Zeta potential 
(mV) ± SD 
Drug loading 
content (%) ± 
SD  
Encapsulation 
efficiency (%) ± 
SD 
Un-CC MLNPs 31.6 ± 1.0 - 5.4 ±  0.2 NA NA 
CC MLNPs 41.1 ± 0.5 -6.1 ±  0.2 NA NA 
DTX-loaded 
un-CC MLNPs 
42.6 ± 0.5 -6.8 ±  0.3 2.3  ±  0.1 29.5 ±  1.3 
DTX-loaded 
CC MLNPs 
55.3 ± 1.2 -7.9 ±  0.5 6.6  ±  0.3 42.8 ±  0.5 
Cy5-labelled 
CC MLNPs 
54.5  ± 0.2 -3.4 ± 0.3 NA NA 
Cy5-labelled 
un-CC MLNPs 
60.9  ± 0.2 -3.9 ± 0.1 NA NA 
n = 3 ±  SD (standard deviation), NA – not applicable  
 
In vitro drug release study 
In order to assess the responsiveness of crosslinked MLNPs to elevated redox environments, 
DXT-loaded MLNPs were incubated in the presence or absence of the reducing agent glutathione 
(GSH). The role of GSH in cancer cells is complex but it has been extensively reported that 
elevated intracellular levels of GSH are related to protection of these cells through drug resistance 
mechanisms. High levels of GSH have been found in a number of types of cancer cells, including 
those in triple negative breast cancer, as previously discussed.  
 29 
HPLC was used to monitor and compare the release kinetics of DTX from crosslinked and un-
crosslinked MLNPs using the developed quantification method (Figure S11). As shown in Figure 
4A, the DTX-loaded crosslinked MLNPs in PBS (pH 7.4), without the addition of 10 mM of GSH, 
showed slow and minimal release. 
After 30 h of incubation, the cumulative release of DTX from the crosslinked MLNPs reached 
21% and no further release occurred beyond 100 hr. In contrast, DTX-loaded crosslinked MLNPs 
exposed to PBS containing 10 mM of GSH showed a much faster and greater cumulative DTX 
release. In the first 10 hours, the crosslinked MLNPs released more than 60% of DTX and after 40 
h the cumulative release was almost 100%, as shown in Figure 4A. The release of DTX from the 
un-crosslinked MLNPs was faster and to a greater extent in comparison to the DTX-loaded 
crosslinked MLNPs exposed to PBS only. 
However, cumulative DTX release from the un-crosslinked MLNPs, in the presence or absence 
of 10 mM of GSH (Figure 4A-B) was incomplete after 100 hr and significantly less than from the 
crosslinked MLNPs after addition of GSH. These findings showed that crosslinked MLNPs were 
able to retain the drug for prolonged times in PBS (pH 7.4) compared to their un-crosslinked 
counterparts, but that the crosslinked MLNPs were sufficiently sensitive to reducing environments 
that they were able to release their full drug cargo under these conditions. The data also suggest 
that carrying out the bis(azide)-bis(alkyne) crosslinking reaction in the presence of DTX fixed the 
internal structure of the MLNPs and the location of the drug molecules in a different manner to 
that occurring in the un-crosslinked MLNPs. It is likely that much of the cross-linking occurred in 
the ‘outer core’ of the MLNPs, owing to limited diffusion of CuSO4 into the more hydrophobic 
regions of the block co-polymer, thus localising DTX nearer the solvent accessible regions. In turn, 
this would allow the drug molecules to escape more readily from the cross-linked MLNPs on 
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addition of GSH compared to the case for DTX entrapped more deeply in the cores of the un-
crosslinked MLNPs.  
 
 
Figure 4 (A) Analysis of docetaxel (DTX) release from DTX-loaded crosslinked MLNPs with and without 
10 mM of GSH, to mimic a redox and non-redox environment, and DTX-loaded un-crosslinked MLNPs in 
PBS without GSH (B) Analysis of docetaxel (DTX) release from DTX-loaded un-crosslinked MLNPs with 
10 mM of GSH. DTX was quantified by HPLC and each point represents mean ± SD, n=3. (Statistical 
analysis is shown in Figure S15 *p < 0.05, **p < 0.01, two-way ANOVA with Tukey’s post-test). 
 
Metabolic activity/ cytotoxicity analysis 
The metabolic activities of the cells treated with both crosslinked and un-crosslinked empty 
MLNPs were assessed in two different breast cancer cells lines, MCF7, MDA-MB-231 and in 
MCF10A, a non-cancerous mammary cell line, as shown in Figure 5. Cells were exposed to 
different concentrations of MLNPs for 24 h and results demonstrated that both crosslinked and un-
crosslinked MLNPs did not show in vitro cytotoxicity under the tested conditions. As apparent 
from Figure 5, the metabolic activity of the cells in the presence of MLNPs was always at least 
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80% of negative controls for all the cell lines tested. The metabolic activity results were similar to 
those reported for other copolymer MLNPs based on PLA and PCL as hydrophobic blocks and 
PEG as a hydrophilic shell, and also with crosslinked micellar formulation using PCL [47].  
 
Figure 5 Metabolic activities of cells incubated with crosslinked and un-crosslinked MLNPs (MTS assay). 
Two breast cancer cell lines and a non-cancerous human breast epithelial cell line MCF10A were used: 
MCF7, MDA-MB-231 and MCF10A. Error bars show standard deviation (n=5). (*p < 0.05, **p < 0.01, 
two-way ANOVA with Tukey’s post-test). 
 
The cytotoxicity of DTX-loaded crosslinked and un-crosslinked MLNPs was also assessed by 
MTS assays in MDA-MB-231 triple negative breast cancer cells, MCF7 breast cancer cells and 
normal MCF10A mammary breast cells (Figure 6). Before assessing the in vitro efficacy of the 
DTX-loaded MLNPs, the intracellular GSH levels were evaluated using a luminescent-based assay 
in the mentioned cell lines, as shown in Figure 6A. The results show that MCF7 cells presented 
the highest levels of intracellular GSH, followed by the MDA-MB-231 and the non-cancerous 
mammary cells which corroborates with previous reports [48, 49]. It should be noted that MCF7 
cells are from an immortalised human estrogen-positive breast cancer cell line. However, when 
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considering patient-derived breast tumours, correlations between progesterone or estrogen 
receptor levels with high levels of GSH have not been reported. It has been shown that hormone-
positive primary breast tumours tend not to present GSH as a marker of malignancy, in contrast to 
triple negative breast cancer subtypes [11, 50, 51]. In this context, taking into account that breast 
cancer is a very heterogeneous disease, the existing in vitro models are not always able to mimic 
human breast tumours. Thus while the results in Figure 6A indicate that the MCF7 cells exhibited 
high GSH content, it is likely that this breast cancer cell line might not be representative of true 
human breast cancers for the specific aspect investigated. As discussed elsewhere [52, 53], 
although presenting limitations, when immortalised breast cancer cells are used towards the 
appropriate investigations, they can be powerful tools for the understanding the clinical aspects of 
breast cancer. Therefore, in order to investigate the responsiveness and efficacy of the DTX-loaded 
crosslinked MLNPs, all three cell lines were treated with the MLNPs and free docetaxel and the 




Figure 6 (A) Intracellular GSH levels of MCF7, MDA-MB-231 and MCF10A cells assessed by GSH-
Glo™ Glutathione Assay. Cell viability of DTX-loaded crosslinked, un-crosslinked MLNPs and free DTX 
(MTS assay) of (B) MCF7, (C) MDA-MB-23 and MCF10A cells. Error bars show standard deviation (n=5). 
(*p < 0.05, **p < 0.01, ****p < 0.0001 two-way ANOVA with Tukey’s post-test). 
According to Figure 6B-D, the metabolic activity of the MCF7 cells treated with DTX-loaded 
crosslinked MLNPs was significantly lower than that of the cells treated with un-crosslinked 
MLNPs and free DTX for all the concentrations tested from 7 to 40 µg/mL of DTX. For the MDA-
MB-231, there were significant differences between the treatments up to 40 µg/mL of DTX, but 
none at the highest concentration. This was likely due to a maximum inhibition of cell metabolic 
activity at this high concentration of drug. For the concentrations from 7 to 20 µg/mL the DTX-
loaded crosslinked MLNPs were also more effective than un-crosslinked MLNPs and free DTX. 
Since both polymer-only formulations did not affect MCF7 and MDA-MB-231 cell activity, the 
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high cytotoxicity of the drug-loaded crosslinked MLNPs can be attributed to the enhanced 
intracellular delivery of DTX and the fact that the stimuli-responsive MLNPs may enhance the 
release of DTX due to the increased glutathione levels in the triple negative and breast cancer cells, 
as shown in Figure 6A [54].  
To corroborate with the hypothesis that the higher in vitro efficacy of the crosslinked MLNPs 
can be attributed to the increased intracellular glutathione levels of the breast cancer cells, the 
efficacy of the formulations and free DTX was also investigated in the healthy mammary epithelial 
cell line, MCF10A. As shown in Figure 6D, the DTX-loaded crosslinked MLNPs were 
significantly less cytotoxic than the un-crosslinked MLNPs and free DTX. The free DTX presented 
the highest toxicity levels against the healthy cells, showing a lack of selectivity in between normal 
and cancer cells. These findings suggest the importance of the development of more clinically 
relevant drug delivery systems which can result in more effective treatment with fewer side effects 
for patients, especially for breast cancers where altered redox states may be present within their 
tumours.  
 
Cell uptake studies in TNBC monolayers (2D) and spheroids (3D) 
2D monolayers of TNBC cells 
The in vitro uptake of Cy5-labelled crosslinked and un-crosslinked MLNPs in 2D monolayers 
of TNBC was investigated using flow cytometry and confocal microscopy. 
Flow cytometry was used to evaluate if the uptake was dependent on the micelle concentration. 
Therefore, cells were incubated with various concentrations (from 10 µg/mL to 150 µg/mL) of 
MLNPs for 4 h. Figure 7A and B shows the FACS histograms of evaluated concentrations of 
crosslinked and un-crosslinked MLNPs. With increasing concentration of MLNPs incubated with 
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the cells, there were increased detected fluorescence intensities, suggesting that more MLNPs were 
internalised per cell, or that more cells were internalising labelled MLNPs compared to the 
negative control (unexposed cells). Figure 7C indicates the difference in the uptake of Cy5-labelled 
crosslinked and un-crosslinked MLNPs according to the mean fluorescence intensity (MFI) 
calculated using Kaluza 1.5 software, and these results demonstrated that Cy5-labelled crosslinked 
MLNPs were internalised to a greater extent than the un-crosslinked MLNPs in 2D monolayers. 
These results suggest that crosslinking the micelle-core did not prejudice the cellular uptake of the 
MLNPs into the TNBC cells. The higher cellular uptake of the Cy5-labelled crosslinked MLNPs 
compared to the un-crosslinked counterparts can be correlated to the size of the MLNPs as shown 
in Table 1. The empty and DTX-loaded un-crosslinked MLNPs are smaller in size when compared 
to the crosslinked MLNPs, however, the opposite is observed when comparing the Cy5-labelled 
formulations. The covalent incorporation of the dye into the polymer backbone seems to have 
played a role on the cellular uptake of the MLNPs and this can be correlated to the fact that the 
crosslinked MLNPs possibly have the ability to allow the hydrophobic dyes to organise in a more 
tightly packed manner in the covalently linked core of the micelles in comparison to the un-
crosslinked MLNPs [55].  
The intracellular uptake of Cy5-labelled crosslinked and un-crosslinked MLNPs was also 
assessed by confocal microscopy. MDA-MB-231 cells were exposed to MLNPs at the 
concentration of 50 µg/mL for 4 h and analysed, as shown in Figure 7D-K. Figure 7D-G shows 
that crosslinked MLNPs were internalised by the triple negative breast cancer cells. In Figure 7H-
K it can be observed that un-crosslinked MLNPs were also taken up by the cells, but this was to a 
lower extent than the crosslinked MLNPs, which corroborates with the FACS data discussed 
above. As can be observed in Figure 7 (D-K), Cy5 signals from the crosslinked MLNPs seemed 
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to be distributed in both the cell membranes (green, stained by CellMask™ green) and also in the 
cytoplasm, whereas the un-crosslinked micelles appeared to be more located in the cell membranes 
only in comparison to crosslinked MLNPs. Nevertheless, both formulations were efficiently 
internalised, as shown in Figure 7.  
 
 
Figure 7 Cellular uptake of Cy5-labelled crosslinked and un-crosslinked MLNPs by MDA-MB-231 breast 
cancer cells after 4 h of incubation. (A,B) FACS uptake histograms for crosslinked (left) and un-crosslinked 
(right) MLNPs show uptake is dependent on the concentration of the MLNPs (C) Quantification of MFI 
with concentration of the Cy5-labelled crosslinked and un-crosslinked MLNPs. Data are representative of 
three experiments. *P < 0.05, t-test. Confocal microscopy images of MDA-MB-231 breast cancer cells after 
4 h of incubation with Cy5-labelled crosslinked and un-crosslinked MLNPs. (D,H) – Green channel: 
showing the green fluorescence of CellMask green plasma membrane stain. (E,I) – Red channel: Cy5-
labelled crosslinked MLNPs and un-crosslinked MLNPs.  (F,J-G,K) – Merged: superimposition of all 
channels and brightfield – Scale bar 50 µm. 
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3D multicellular spheroids of TNBC cells 
The uptake of Cy5-labelled MLNPs was assessed in 3D multicellular tumour spheroids of MDA-
MB-231 cells using FACS and confocal microscopy. Results and discussion are shown in the 
Supportive Information and in Figure S12.  
In addition to the assessment of the Cy5-labelled MLNPs uptake in a TNBC 3D spheroid 
monoculture model, the uptake was also investigated in a co-culture 3D model consisting of MDA-
MB-231 and cancer-associated fibroblasts transfected with GFP.  The uptake was assessed by 
FACS and images of the spheroids were also obtained with a confocal microscope as shown in 






































































Figure 8 - Cellular uptake of Cy5-labelled crosslinked and un-crosslinked MLNPs by spheroids of MDA-
MB-231 TNBC cells and cancer-associated fibroblasts (CAFs) (2000:2000) after 5 h of incubation. (A) 
FACS histograms showing the population of cells untreated and treated with Cy5-labelled crosslinked and 
un-crosslinked MLNPs (C) MFI of the Cy5 positive cells distinguishing GFP positive cells (CAFs) and 
GFP negative cells (MDA-MB-231s). Data are representative of three experiments. (*p < 0.05, **p < 0.01, 
****p < 0.0001 two-way ANOVA with Tukey’s post-test). Confocal microscopy images of spheroids of 
MDA-MB-231 TNBC cells and cancer-associated fibroblast after 5 h of incubation with Cy5-labelled 
crosslinked and un-crosslinked MLNPs. (C,G) – Blue channel: showing nuclei stained with Hoechst. (D,H) 
– Red channel: Cy5-labelled crosslinked MLNPs and un-crosslinked MLNPs.  (E,I) GPF-transfected CAFs 
cells (F,J) – Merged: superimposition of all channels – Scale bar 200 µm. 
Figure 8A,B shows the population of cells untreated (negative control) and cells treated with 
Cy5-labelled crosslinked and un-crosslinked MLNP. Cy5 positive cells are in the top (CAFs) and 
bottom right (MDA-MB-231) of the FACS histograms. In Figure 8B is presented the MFI of the 
Cy5-positive cells encompassing MDA-MB-231 cells and CAFs transfected with GFP. As can be 
observed, overall the Cy5-labelled crosslinked MLNP were internalised to a greater extent than 
the un-crosslinked MLNPs in the co-culture 3D spheroids. When distinguishing the cell 
populations, it is possible to observe that the uptake of the crosslinked MLNPs was higher due to 
the extended uptake into the triple negative breast cancer cells, MDA-MB-231. Regarding the 
uptake in CAFs, there was no difference in the MFI values for the crosslinked and un-crosslinked 
MLNPs.   
In Figure 8 (C,J) are shown the results of the uptake assessed by confocal microscopy. Spheroids 
nuclei were also stained with Hoechst 33342 dye at concentration of 1 µg/mL (50 µL) for 30 
minutes. The Cy5-labelled MLNPs penetrated within the spheroids as shown in Figure 8 D,H and 
in E,I is presented the CAFs transfected with GFP. Finally, the merged images of the channels are 
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shown in Figure 8 F,J. The fluorescence images corroborate with the FACS data as they 
demonstrate that both Cy5-labelled MLNPs were taken up by the spheroids, however, the 
crosslinked MLNPs seem to have been taken up to a greater extent when compared with the un-
crosslinked MLNPs.   
Comparing Figures 8 and S12, it is noticeable that the addition of CAFs in the 3D spheroids of 
TNBC cells MDA-MB-231 made the resultant spheroids more compact and thus more relevant as 
a biological in vitro model to mimic TNBC tumours than the monocultures. The addition of 
fibroblasts in 3D spheroid models has been reported to increase the resistance, promote the 
modification of signalling pathways, contribute to extracellular matrix environment and promotes 
cell migration and invasion,[56, 57] and thus the results in the co-culture model in which the cross-
linked MLNPs penetrated to the greatest extent were indicative of the promise of this formulation. 
3D cell culture is notably more reliable in mimicking the cellular microenvironment in vivo [58] 
and the obtained results are closer to what is expected from the behaviour of nanoparticles in the 
in vivo environment.  
 
Efficacy of MLNPs and free docetaxel in 2D and 3D cell culture 
Apoptosis assays in 2D monolayers  
Cells were treated with free DTX, DTX-loaded crosslinked and un-crosslinked MLNPs for 24 
h. After the specified incubation time, an annexin-V/PI assay was used to discriminate between 
viable, apoptotic and dead cells using flow cytometry. Three different controls were prepared as 
shown in Figure 9A. It shows the controls used for observing the basal level of apoptosis, and also 
the autofluorescence of MDA-MB-231 cells. Figure 9B shows cell populations treated with free 
DTX and DTX-loaded MLNPs. Live cells which were negative for annexin-V and PI are depicted 
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in quadrant 3 (Q3). Early apoptotic cells that are positive for annexin-V are located in Q4. Double-
positive cells (annexin-V and PI positive), which are considered to be cells in the late stages of 
apoptosis are shown in Q2, while, Q1 shows necrotic cells that are positive only for PI.  
The proportions (%) of different cell populations in each stage are presented in Figure 9C, 
compared to controls in Figure 9A, considering the basal level of apoptosis and the 
autofluorescence of cells (negative control). Cells exposed to crosslinked MLNPs were more 
apoptotic (considering early and late apoptosis) to a level of 31%, followed by un-crosslinked 
MLNPs (25%) and free DTX (23%) of apoptotic cells. DTX is a microtubule-disruptive apoptotic 
drug and as shown in Figure 9A-C, DTX-loaded crosslinked MLNPs increased the DTX-induced 
apoptosis in comparison to the un-crosslinked MLNPs and also, to the free drug. 
Caspase activity was also assessed in the MDA-MB-231 cells treated for 24 h with free drug, 
DTX-loaded crosslinked and un-crosslinked MLNPs using the CellEventTM caspase-3/7 green 
detection reagent combined with SYTOXTM AADvanced red. Thus, in this assay apoptotic cells 
with activated caspase 3/7 were discriminated from necrotic cells using flow cytometry. The 
distribution of cell populations exposed to free DTX and DTX-loaded MLNPs is shown in Figure 
9D-E. In Q3 are the viable cells which are negative for CellEventTM Caspase 3/7 and SYTOXTM 
red, whereas Q4 shows apoptotic cells which are positive for CellEventTM Caspase 3/7. Necrotic 
cells (Q2) are positive for SYTOXTM red and for CellEventTM Caspase 3/7.   
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Figure 9 Apoptosis assays annexin-V/ PI and caspase 3/7 and Sytox assessed for the MDA-MB-231 cells 
treated with DTX-loaded crosslinked and un-crosslinked MLNPs (A) Controls in the panels showing 
unstained MDA-MB-231 breast cancer cells and controls for annexin-V FITC and PI.  (B) MDA-MB-231 
breast cancer cells stained with annexin-V FITC and PI, following treatment with crosslinked and un-
crosslinked MLNPs encapsulated with DTX and free DTX for 24 h. Samples were analysed by flow 
cytometry.  (C) Showing the proportion (%) of different cell populations after treatment with crosslinked, 
un-crosslinked MLNPs and free DTX using annexin/PI assay. (D) Controls in the panels showing unstained 
MDA-MB-231 breast cancer cells and controls for CellEvent Caspase 3/7 and Sytox. (E) MDA-MB-231 
triple negative breast cancer cells were treated with crosslinked and un-crosslinked MLNPs encapsulated 
with DTX and free DTX for 24 h. Samples were labeled with the CellEvent Caspase 3/7 and Sytox red and 
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analysed by flow cytometry. (F) Cells with caspase-3/7 activation after treatment with crosslinked, un-
crosslinked MLNPs and free DTX.  
All treatments promoted activation of caspase-3/7 in MDA-MB-231 cells, but cells treated with 
crosslinked MLNPs had a higher percentage caspase-3/7 activation in comparison to the cells 
treated with un-crosslinked MLNPs and free DTX (Figure 9F). 
 
Live/Dead assay in 3D spheroids  
The efficacy of the DTX-loaded crosslinked and un-crosslinked MLNPs and free DTX in 3D 
spheroids was assessed by a live/dead staining assay using calcein-AM and ethidium homodimer-
1 (EthD-1). After seeding the cells (4000 cells per well), the spheroids were formed within 3 days 
and were exposed to DTX-loaded crosslinked and un-crosslinked MLNPs and free DTX for 24 h. 
Spheroids were washed with PBS and subsequently stained with 2 M of calcein AM and 4 M 
of EthD-1 solutions and incubated for 1 h at room temperature. Afterwards, spheroids were 
carefully washed with PBS and fixed with 4% paraformaldehyde solution for confocal microscopy 
analysis, or disintegrated prior to plate reader-based quantitative analysis.  
As seen in Figure 10, the green fluorescent cells in the spheroids are live cells which present 
ubiquitous intracellular esterase activity, allowing the nonfluorescent cell-permeant calcein AM to 
be converted to the highly fluorescent calcein inside these cells. Dead cells displayed red 
fluorescence due to membrane damage which allowed the penetration of EthD-1 within the cells.  
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Figure 10 Live/Dead spheroid staining using calcein AM (live cells) and ethidium homodimer-1 (dead 
cells). Spheroids were treated (24h) with DTX-loaded crosslinked (A), DTX-loaded un-crosslinked MLNPs 
(B) and free Docetaxel (DTX) (C), at the concentration of 7 g/mL of DTX. Spheroids were imaged using 
confocal microscopy. (D) Quantitative data of the live/dead spheroids staining obtained by quantification 
of the fluorescence intensity.  
In Figure 10-AC is shown the confocal images of the live and dead cells within the spheroids 
after treatment with DTX-loaded crosslinked and un-crosslinked MLNPs and free DTX. Figure 
10C is shown the quantitative data obtained by reading the plates containing the disintegrated 
spheroids using a fluorescence multi-well plate reader. As the results indicate, the spheroid treated 
with DTX-loaded crosslinked MLNP induced the highest amount of TNBC cell death (red cells) 
in comparison to the spheroids treated with DTX-loaded un-crosslinked MNLP and free DTX. 
This result showed that the DTX-loaded crosslinked MLNPs had a superior efficacy even in more 
complex in vitro model (3D spheroids) which present higher innate resistance to drug treatments 
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[59]. Images of negative control (untreated spheroid) and positive control (spheroid treated with 
12% of DMSO) are shown in Figure S13. 
 
CONCLUSIONS 
In summary, we have designed DTX-loaded redox-responsive crosslinked MLNPs as potential 
TNBC therapeutics, using a PEG-poly(lactide-co-caprolactone) terpolymer functionalised such 
that the degradable linkers were placed in the caprolactone units to modulate accessibility to TNBC 
cellular reductants. The crosslinked MLNPs exhibited high uptake in TNBC 2D monolayers and 
also in 3D multicellular spheroid models, monoculture and in a relevant co-culture of TNBC cells 
with cancer-associated fibroblasts. The reducible-responsive crosslinked MLNPs released higher 
amounts of drug under redox conditions than the non-reducoble analogues.  It was shown that the 
DTX-loaded reducible crosslinked MLNPs displayed higher cytotoxicity against breast cancer cell 
lines (including TNBC) with high intracellular amounts of GSH compared to the un-crosslinked 
MLNPs. TNBC cells treated with DTX-loaded crosslinked MLNPs also showed increased 
caspase-3/7 activation. In addition, the levels of early and late apoptosis combined were also higher 
in TNBC cells exposed to the DTX-loaded crosslinked formulations. Regarding efficacy against 
3D tumour spheroids, DTX-loaded crosslinked MLNP also showed higher activity in comparison 
to the un-crosslinked counterparts and to free DTX. Overall, the responsive crosslinked MLNPs 
were demonstrated to be more effective across multiple assays than the non cross-linked analogues 
and the free drug. These data together suggest that MLNPs might be a promising treatment for 
future applications in triple negative breast cancer. However, it will be necessary to demonstrate 
that the MLNPs are sufficiently stable to circulate following systemic injection, and it is likely that 
some form of targeting will be needed to enable the polymers to penetrate into tumour tissue 
 45 
preferentially compared to healthy regions. This might be achieved by addition of ligands at the 
surface of the micelles which could bind to over-expressed receptors, but as this approach has had 
limited success in many cases, it might also be necessary to utilise external stimuli such as 
ultrasound or local tissue heating to enhance permeability within the tumour. Therefore, given the 
encouraging results obtained from the clinically relevant 3D models, experiments to assess the in 
vivo efficacy in a tumour-bearing model of TNBC will be the next step to investigate further the 
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